DaVita Inc. (NYSE:DVA) Shares Sold by Dumont & Blake Investment Advisors LLC

Dumont & Blake Investment Advisors LLC lessened its position in DaVita Inc. (NYSE:DVA) by 50.1% in the 3rd quarter, Holdings Channel reports. The fund owned 7,056 shares of the company’s stock after selling 7,094 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in DaVita were worth $1,157,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. lifted its position in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. acquired a new position in DaVita during the second quarter worth $43,000. Versant Capital Management Inc lifted its holdings in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Friedenthal Financial purchased a new stake in shares of DaVita during the 2nd quarter worth $48,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of DaVita during the 2nd quarter worth $68,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the topic of a number of research analyst reports. UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America increased their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. TD Cowen increased their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, DaVita currently has a consensus rating of “Hold” and an average price target of $159.00.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock worth $27,387,069 in the last ninety days. Insiders own 2.00% of the company’s stock.

DaVita Trading Down 2.3 %

NYSE DVA traded down $3.78 during trading hours on Friday, hitting $157.60. 9,580 shares of the company’s stock were exchanged, compared to its average volume of 798,917. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The firm has a market capitalization of $13.22 billion, a P/E ratio of 17.19, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The business’s 50 day moving average is $157.95 and its 200-day moving average is $145.34. DaVita Inc. has a 12-month low of $75.47 and a 12-month high of $168.50.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the company earned $2.08 earnings per share. As a group, analysts anticipate that DaVita Inc. will post 9.99 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.